Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Titan Pharmaceuticals

Titan Pharmaceuticals

Titan Pharmaceuticals is a small Molecules founded in 1992.

Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases.

Titan Pharmaceuticals, Inc. is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

ProNeura consists of a small, semi-rigid, flexible implant made from a mixture of EVA (ethylene-vinyl acetate) and a drug substance. The resulting product is a solid matrix implant that is placed subcutaneously, normally in the inner part of the upper arm, in a simple office procedure and is removed in a similar manner at the end of the treatment period. These procedures may be performed by trained health care providers, or HCPs, including licensed and surgically qualified physicians, nurse practitioners, and physician’s assistants in a HCP’s office or other clinical setting.

Titan’s first product based on its ProNeura technology was Probuphine® (buprenorphine) implant, which was approved in the United States, Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine, In October 2020, Titan announced its decision to discontinue selling its Probuphine implant in the U.S. and wind down its commercialization activities, and to pursue a plan that will enable it to focus on its ProNeura-based product development programs. For additional information regarding Probuphine, click here.




Further Resources



Search on Google
Search on Bing
Titan Pharmaceuticals, Inc.
June 23, 2021
/PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021,"...
Titan Pharmaceuticals, Inc.
January 15, 2021
/PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited...
Titan Pharmaceuticals, Inc.
November 30, 2020
/PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30...


Golden logo
By using this site, you agree to our Terms & Conditions.